Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst programme.
Alongside backing from the Company’s investors, this award from the UK’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias.